Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients.
about
Human parvovirus B19.Hemophagocytic syndromes and infectionGenotype 3b of human parvovirus B19 detected from hospitalized children with solid malignancies in a North Indian tertiary care hospital.The role of parvovirus B19 infection in childhood acute lymphoblastic leukemia.New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infectionsPathogenesis of human parvovirus B19 in rheumatic disease.Parvovirus B19 infection in pediatric transplant patientsIncreased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy.Parvovirus B19 outbreak on an adult ward.Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19.Clinical aspects of parvovirus B19 infection.Parvovirus B19-associated transient red cell aplasia in children: the role of bone marrow examination in unusual presentations.Parvovirus: the expanding spectrum of disease.Infection-associated hemophagocytic syndrome complicated by infectious lymphoproliferation: a case report.Parvovirus B19 infection. Associated diseases, common and uncommon.Is routine viral screening useful in patients with recent-onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study.Pure red cell aplasia due to parvovirus B19 infection transmitted probably through hematopoietic stem cell transplantation.Parvovirus B19 infection and Diamond-Blackfan anaemia.Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies
P2860
Q24532891-BDF95CBC-C898-4E7E-8CE0-D33A213E0B80Q24653852-7A2C1440-BAE3-44AD-A45A-4FBDB9F4B5D4Q33431762-2A4A186B-55CD-4019-86AF-C71E242F6214Q33688408-2AF75198-610C-4AD0-A1B5-770BA69FD7AFQ33974299-04731645-FEE2-44BD-877A-88A1BE0BD359Q34024904-13562D7B-0C00-43C5-BB53-E968C4842395Q34299511-EC778D9F-49D4-4528-A7CC-D6B63A0A2811Q34437553-7652A3FC-2A3B-49D8-9131-28B53008CEC6Q36504248-BE84D347-C2F2-4753-942C-084CFAB6B597Q36522202-EB3449DD-3D5A-463D-826B-42F48841F855Q36589340-18168958-037A-45EB-BC2E-DA952BA5DFDDQ40520746-EF2E9277-5491-4D6D-A9CE-9D947C941D2BQ40529640-64B03116-A885-4E8B-A99E-66CB754ED588Q40671517-84112276-9ED0-479F-B4BF-A01D5C736939Q41007475-0F6D7CC4-0E7A-4C83-8DEA-AF49A072A846Q44011576-1491B350-67E9-4EB1-9DF2-7D9F45D49952Q50688064-B1FD83E4-359C-4EFB-B324-9281A7BF58D6Q54529573-D8F8E977-0FCD-43C6-9ADA-4EA1FE44D90DQ58001976-68B8161F-675D-4543-93D9-BE8A1E46F82B
P2860
Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Manifestations and treatment o ...... in immunocompromised patients.
@en
type
label
Manifestations and treatment o ...... in immunocompromised patients.
@en
prefLabel
Manifestations and treatment o ...... in immunocompromised patients.
@en
P2093
P1476
Manifestations and treatment o ...... in immunocompromised patients.
@en
P2093
P304
P356
10.1016/S0022-3476(05)82820-3
P407
P577
1990-03-01T00:00:00Z